Kinneret Livnat Savitzky

Dr. Kinneret Livnat Savitzky joined Compugen’s Board of Directors in 2018. Dr. Livnat Savitzky has significant experience in the life sciences industry, including drug discovery and development, corporate partnering and capital raising. She currently serves as the CEO and a board member of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation and Takeda Ventures Inc. (the venture group of Takeda Pharmaceutical Company). As part of her role at FutuRx she also serves as a chairperson or board member in several of the FutuRx portfolio companies. Dr. Livnat Savitzky also serves as an active chairperson in KAHR Medical and as a director in Hadasit Medical Research and Development, DreaMed Diabetes and Biomica. Previously, Dr. Livnat Savitzky served as CEO of BioLineRx Ltd. a drug development company focused on oncology. Previously, Dr. Livnat Savitzky held various R&D management positions at BioLineRx and Compugen. Dr. Livnat Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction in Human Genetics from Tel Aviv University.